{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:17:16Z","timestamp":1792192636224,"version":"4.4.0"},"reference-count":72,"publisher":"Wiley","issue":"s9","license":[{"start":{"date-parts":[[2005,11,18]],"date-time":"2005-11-18T00:00:00Z","timestamp":1132272000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:p><jats:bold>Summary:\u2002<\/jats:bold>Since its introduction into clinical practice in 1999, levetiracetam, the S enantiomer of piracetam, has rapidly found a secure place, initially in the therapy of partial onset seizures and subsequently in the treatment of idiopathic generalized epilepsies (IGE). It has many of the properties of an \u201cideal\u201d antiepileptic drug, including rapid absorption, linear pharmokinetics, and sparse drug interactions. Tolerabiliy is generally excellent in both adults and children, although tiredness is a common dose\u2010limiting adverse effect. Occasionally the drug can precipitate behavioral abnormalities, especially in patients with learning disability. There is a wide safety margin in overdose. In common with most antiepileptic drugs its mode of action remains uncertain. Levetiracetam binds to a specific site in the brain, influences intracellular calcium currents and reverses negative allosteric modulators of GABA\u2010 and glycine\u2010gated currents in vitro. Its effectiveness has been demonstrated in animal models of epilepsy and in clinical trials of partial onset and IGE. Treatment of IGEs may be straightforward, with many patients demonstrating an excellent and robust response to valproate monotherapy. However, there remains a significant minority of patients for whom valproate is unsuitable, including those who experience unacceptable adverse effects (e.g., weight gain or hair loss) and women of childbearing age in whom the teratogenic potential of valproate is unacceptable. Therapeutic response to lamotrigine in this group is often disappointing, and many clinicians now are turning to the choice of levetiracetam. Efficacy in generalized tonic\u2013clonic seizures and myoclonus is usually apparent and some patients experience improvement in typical absences. Experience of combinations of levetiracetam with other antiepileptic drugs is limited in IGE and the responses are largely anecdotal. In our hands, patients with refractory IGEs may respond to combinations of levetiracetam with valproate, lamotrigine, and phenobarbital, and adverse effects when they occur are usually limited to tiredness. Levetiracetam does not interact with the oral contraceptive pill, simplifying treatment in women of childbearing age. Although animal data look encouraging, questions over levetiracetam's teratogenic potential and overall safety in pregnancy will remain for many years to come.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2005.00329.x","type":"journal-article","created":{"date-parts":[[2005,11,18]],"date-time":"2005-11-18T19:50:25Z","timestamp":1132343425000},"page":"154-160","source":"Crossref","is-referenced-by-count":32,"title":["Levetiracetam in the Treatment of Idiopathic Generalized Epilepsies"],"prefix":"10.1111","volume":"46","author":[{"given":"Richard","family":"Gr\u00fcnewald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,11,18]]},"reference":[{"key":"e_1_2_9_2_2","unstructured":"Levetiracetam summary of product characteristics. UCB Pharma February 2004."},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.20041020.x"},{"key":"e_1_2_9_4_2","first-page":"351","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"67","author":"Patsalos PN","year":"1995","journal-title":"Pharmacol Ther"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443110-00002"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200312000-00007"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2005.01.005"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00309-6"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00436-O"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.08.033"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0953-816X.2003.03106.x"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2003.12.004"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.02204.x"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(01)01884-5"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200303030-00035"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704766"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.079327"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(03)00248-X"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90855-X"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00077-1"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1984.tb04196.x"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2004.02.002"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200103050-00006"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2003.08.006"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb04605.x"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.2.236"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00323.x"},{"key":"e_1_2_9_29_2","unstructured":"VerdruP WajgtA DelgadoJS et al.Efficacy and safety of levetiracetam 3000 mg\/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalized epilepsy with myoclonic seizures.Epilepsia2005;46(suppl 6):56."},{"key":"e_1_2_9_30_2","unstructured":"Data on file. UCB Pharma."},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)00031-9"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0380"},{"key":"e_1_2_9_33_2","unstructured":"ReisJ KnakeS HamerHM OertelWHet al.Efficacy and tolerability of levetiracetam in the treatment of focal and generalized epilepsy.12th Meeting of the European Neurological Society Berlin Germany June 2002. Abstract P281."},{"issue":"8","key":"e_1_2_9_34_2","first-page":"153","article-title":"A pilot study of levetiracetam in patients with generalized epilepsy","volume":"43","author":"Beran R","year":"2002","journal-title":"Epilepsia"},{"issue":"8","key":"e_1_2_9_35_2","first-page":"153","article-title":"Levetiracetam in idiopathic generalized epilepsies","volume":"43","author":"Meencke H","year":"2002","journal-title":"Epilepsia"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(02)00273-X"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(03)00139-0"},{"issue":"8","key":"e_1_2_9_38_2","first-page":"80","article-title":"Levetiracetam monotherapy in generalized epilepsy and photosensitivity","volume":"44","author":"Covanis A","year":"2003","journal-title":"Epilepsia"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2003.06.001"},{"issue":"1","key":"e_1_2_9_40_2","first-page":"S39","article-title":"Levetiracetam: preliminary efficacy in generalized seizures","volume":"5","author":"Kasteleijn\u2010Nolst Trenite DG","year":"2003","journal-title":"Epileptic Disord"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.451006.x"},{"key":"e_1_2_9_42_2","first-page":"271","volume-title":"The epilepsies: seizures, syndromes and management","author":"Panayiotopoulos CP","year":"2005"},{"issue":"7","key":"e_1_2_9_43_2","first-page":"179","article-title":"Effect of levetiracetam on resistant juvenile myoclonic epilepsy","volume":"43","author":"Greenhill L","year":"2002","journal-title":"Epilepsia"},{"key":"e_1_2_9_44_2","unstructured":"ResorSR ResorLD.Levetiracetam monotherapy in the treatment of convulsive seizures in juvenile myoclonic epilepsy.Presented at the 54th Annual Meeting of the American Academy of Neurology April 1320 2002; Denver CO ."},{"issue":"8","key":"e_1_2_9_45_2","first-page":"153","article-title":"Promising results of levetiracetam in juvenile myoclonic epilepsy","volume":"43","author":"Jongsma M","year":"2002","journal-title":"Epilepsia"},{"issue":"3","key":"e_1_2_9_46_2","first-page":"141","article-title":"The effectiveness of levetiracetam in drug\u2010resistant juvenile myoclonic epilepsy","volume":"45","author":"Czapinski PP","year":"2004","journal-title":"Epilepsia"},{"issue":"3","key":"e_1_2_9_47_2","first-page":"141","article-title":"Levetiracetam is effective in juvenile myoclonic epilepsy","volume":"45","author":"La Neve A","year":"2004","journal-title":"Epilepsia"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.02141.x"},{"key":"e_1_2_9_49_2","first-page":"66","article-title":"Treatment of myoclonus","volume":"103","author":"Van Zandijcke M","year":"2003","journal-title":"Acta Neurol Belg"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.44.s11.5.x"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000110193.78872.DD"},{"key":"e_1_2_9_52_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1684\/j.1950-6945.2000.tb00445.x","article-title":"Antimyoclonic effect of levetiracetam","volume":"2","author":"Genton P","year":"2000","journal-title":"Epileptic Disord"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.6.1112"},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.3.411"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10027"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3798(03)00041-2"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(03)00193-6"},{"issue":"3","key":"e_1_2_9_58_2","first-page":"68","article-title":"Tolerability of levetiracetam in 516 patients; analysis by dose and serum concentration","volume":"45","author":"Weintraub D","year":"2004","journal-title":"Epilepsia"},{"key":"e_1_2_9_59_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.32101.x"},{"key":"e_1_2_9_60_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1684\/j.1950-6945.2003.tb00573.x","article-title":"Acute psychosis associated with levetiracetam","volume":"5","author":"Youroukos S","year":"2003","journal-title":"Epileptic Disord"},{"key":"e_1_2_9_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059131102001723"},{"key":"e_1_2_9_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2003.07.008"},{"key":"e_1_2_9_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(02)00251-0"},{"key":"e_1_2_9_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(03)00154-7"},{"key":"e_1_2_9_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(03)00111-0"},{"key":"e_1_2_9_66_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004703-200208000-00006"},{"key":"e_1_2_9_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2003.12.005"},{"issue":"1","key":"e_1_2_9_68_2","first-page":"15","article-title":"Levetiracetam induced polyneuropathy: a case report","volume":"45","author":"Kapoor P","year":"2005","journal-title":"Electromyography & Clinical Neurophysiology"},{"key":"e_1_2_9_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.64903.x"},{"key":"e_1_2_9_70_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.21503.x"},{"key":"e_1_2_9_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2003.08.009"},{"key":"e_1_2_9_72_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.57701.x"},{"key":"e_1_2_9_73_2","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120016959"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2005.00329.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2005.00329.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T18:44:43Z","timestamp":1736102683000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2005.00329.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":72,"journal-issue":{"issue":"s9","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1111\/j.1528-1167.2005.00329.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2005.00329.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}